Lupin Launches Tavaborole Topical Solution in the United States

Global pharma major Lupin Limited (Lupin) today announced the U.S. launch of Tavaborole Topical Solution, 5% having received an approval from the United States Food and Drug Administration (FDA). The product will be manufactured at Lupin's facility in Pithampur, India.

Tavaborole Topical Solution, 5%, is generic equivalent of Kerydin® Topical Solution, 5%, of Anacor Pharmaceuticals, Inc. and is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.

Tavaborole Topical Solution (RLD: Kerydin®), 5% has an estimated annual sales of USD 53 million in the U.S. (IQVIA MAT May 2021).

Shares of LUPIN LTD. was last trading in BSE at Rs.1164.65 as compared to the previous close of Rs. 1152.15. The total number of shares traded during the day was 83554 in over 3731 trades.

The stock hit an intraday high of Rs. 1170 and intraday low of 1151.05. The net turnover during the day was Rs. 97253051.

Source : Equity Bulls

Keywords